about
Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitorPhase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor studyProspective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting.Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltrationPredicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.How to minimise the effect of tumour cell content in detection of aberrant genetic markers in neuroblastoma.Two independent epigenetic biomarkers predict survival in neuroblastomaA comparison of current neuroblastoma chemotherapeutics.Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).Solid ovarian tumours in childhood: a 35-year review in a single institution.Treatment of high-risk neuroblastoma with anti-GD2 antibodies.New prognostic markers in neuroblastoma.Paediatric tumour boards in Spain: a national survey.Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma.TIAM1 variants improve clinical outcome in neuroblastoma.Advances in emerging drugs for the treatment of neuroblastoma.Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.Herpesvirus-6 encephalitis complicated by Wernicke-Korsakoff syndrome in a pediatric recipient of unrelated cord blood transplantation.Cancer in children and adolescents in Spain: incidence, treatment setting and provider specialty.Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis.Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.Long-term results of high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma patients: a report of the Spanish working party for BMT in children (Getmon).[Value of 123I-MIBG scanning, neuron-specific enolase and serum ferritin in the diagnosis and follow-up of patients with neuroblastoma]Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation.Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients.MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma.PNR-16DIAGNOSIS, MANAGEMENT AND OUTCOME OF CHILDREN WITH CENTRAL NERVOUS SYSTEM (CNS) PRIMITIVE NEUROECTODERMAL TUMORS (PNET) IN SPAIN: A STUDY FROM THE SPANISH NATIONAL PEDIATRIC ONCOLOGY & HEMATOLOGY SOCIETY (SEHOP).HG-128BO25041 - A PHASE II OPEN-LABEL, RANDOMIZED, MULTI CENTRE COMPARATIVE STUDY OF BEVACIZUMAB BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR HIGH GRADE GLIOMA.HG-85INTER-OBSERVER AGREEMENT IN NEUROPATHOLOGICAL HGG DIAGNOSIS : EXPERIENCE OF THE PRE-RANDOMISATION CENTRAL REVIEW IN THE HERBY TRIAL.Survey on paediatric tumour boards in Europe: current situation and results from the ExPo-r-Net project.Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care.Minimal residual disease in neuroblastoma: to GAGE or not to GAGE.A novel TP53 germ-line mutation identified in a girl with a primitive neuroectodermal tumor and her father.Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.1p36 deletion results in a decrease in glycosaminoglycans which is associated with aggressiveness in neuroblastic tumors.Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
P50
Q28534151-AE8F0B60-602D-403A-8183-ADFEBCF7BE1BQ33409117-9ACD147A-E215-42D6-9CEF-C0C307405098Q33735456-6AABB84D-DFDE-4F64-B5AC-6AEA67E4B2C7Q34346730-487EF74D-B7A0-40AC-9D05-98A8CA9010ACQ34606771-ECA9BA2E-F554-4828-A5B9-D9AEA4C0D8EFQ35108352-06E8533B-E97C-41CF-B9DD-A56EE3E7EC55Q35170598-8029E233-8979-4102-950C-FE2EA55E3C99Q35609684-8A247424-A1E9-4BCD-9841-82A0AA1FD7CDQ35653969-28EDA8C0-5852-4CCC-8AF0-0AA04C4119EFQ37750067-2C4CB108-0FFB-40FA-AEEC-D679E88317FEQ37820755-B5F6AC05-1803-4333-97F4-52677C2AF405Q38088418-69F4A6B2-CFAB-4D60-B30F-6A68FA742341Q38384214-348E51D4-B887-4C06-9332-5D50B2EEFE1CQ38758942-0BDFC990-FAD2-4F0D-825A-CDDD65E9D670Q38830217-6B72A01C-1F5B-4079-8A90-675AF653238AQ39158415-467ACEF7-10A0-4456-BD2A-8D28C881A2BEQ39866458-7DE31520-ED25-42CC-9EDF-A952289C0E5BQ40308558-8F05B286-0EAC-4B7F-BA5E-3D333B29B456Q40586361-7A7E6A73-F17D-47DD-8C02-F24078ECA7D4Q40800299-0430D0A0-0B77-4267-B08A-AAD2E73CAAEBQ40881350-23C86BA9-D794-4F25-8ECF-87AE001705D9Q41975973-B14A8275-9222-457E-8487-D375375D9831Q43608093-D3080108-C7B1-4037-B02B-196A532AA9C8Q43680012-D22B2211-D522-4F2D-B9FF-020C141394F6Q43685701-C4EF440E-0781-454B-9990-0AC206F210C0Q44452897-383DD902-600E-4A5E-A4DA-6A676708A858Q44747351-D2CFEC65-9BC2-457F-9757-CB6D73C728ECQ45138010-FF8969A2-D0B0-4548-9007-10812BDB77B4Q45267671-9E7C535C-52C3-44DB-9415-B88CDE8CA51EQ46348301-56665C55-D52C-4285-93A5-29485DFBB4BFQ46351175-560EE537-5BA6-4A5C-AFFE-2FC4FF0D7B92Q46352322-D94E6B73-F391-433E-83D0-185982FDE560Q47192805-CC7F674C-3901-4C11-AE29-E5F06EBB4CDEQ47296254-C264E369-311A-4945-A1E3-FDD06D0F609BQ47321927-1F34254B-91E7-4A41-8E12-67E3E0A2A4DFQ48402893-FB329018-8A96-4C10-97A1-0E1354AB1D1AQ48685455-AC17FCA4-06C7-463B-98B1-4E975E1B0721Q49714713-FEBB6E96-8F30-4E03-945B-3BA4E13868BCQ50140790-CA31DCB0-8311-4697-A130-E180EEF4C0E9Q50853134-C47158D0-F37C-4DBB-B015-D3FF8F4D4000
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adela Cañete
@ast
Adela Cañete
@en
Adela Cañete
@es
Adela Cañete
@nl
Adela Cañete
@sl
type
label
Adela Cañete
@ast
Adela Cañete
@en
Adela Cañete
@es
Adela Cañete
@nl
Adela Cañete
@sl
prefLabel
Adela Cañete
@ast
Adela Cañete
@en
Adela Cañete
@es
Adela Cañete
@nl
Adela Cañete
@sl
P106
P21
P31
P496
0000-0002-5669-5097